As the creation of new drugs for chronic illness progresses, we ask ourselves certain questions when thinking from a biopharmaceutical manufacturer point of view: What key points do biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for distribution networks? What capabilities do they prioritize most highly? What factors benefit patients the most? Three metrics come […]
September 16, 2015 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - In the current landscape of specialty drugs for chronic care, including PCSK9 inhibitors topping $1,000 per month for life, what are the key factors biopharmaceutical manufacturers consider when evaluating specialty pharmacy partners for their distribution networks? We are always interested in learning […]
September 9, 2015 - Curant President and CEO, Patrick Dunham, in Managed Healthcare Executive - In the midst of the shift from fee-for-service to value based healthcare, pharmaceutical manufacturers continue churning out high-priced therapies. They may be justified to do so as long as the outcomes of the medication therapies outweigh the costs. We define “value” as […]
There’s an 80/20 rule when it comes to healthcare – 80% of healthcare cost comes from 20% of the populace, the chronically ill. According to the Deloitte Center for Health Solutions, healthcare spend in the United States is expected to eclipse $4 trillion this year. Take an estimated population of 319 million into consideration; that […]
August 30, 2015 - Curant COO, Marc O'Connor, in MedCity News - If it seems like every industry has some sort of 80-20 rule, that’s because it does. Entrepreneurs will tell you 80 percent of their profits come from 20 percent of their customers. Customer service reps will tell you they spend 80 percent of their time […]
For two days last month in Philadelphia, experts from pharmaceutical manufacturers, pharmacy benefit managers, and specialty pharmacists mingled in an open exchange of information and education at the 2nd Annual Summit on Specialty Distribution and Channel Optimization. There was a lot of talk around the intricacies of open, limited, and closed networks -- but since […]
August 12, 2015 – Atlanta, Georgia – Curant Health, an innovative medication management company, has been named on the Inc. 5000 list of fastest growing private companies in the U.S., having been the only large healthcare company to make the list for three consecutive years. This year Curant ranks #1004 on the prestigious list and is […]
August 13, 2015 - Curant Health COO, Marc O'Connor, in Managed Healthcare Executive - Out of $213 billion in avoidable annual healthcare costs, $105 billion is due to medication nonadherence, according to a recent IMS Health Informatics study. In addition to the potential cost savings associated with improved adherence, it could also lead to better […]
August 5, 2015 - Curant Health President and CEO, Patrick Dunham, in Managed Healthcare Executive - Ultimately, these new Medicare payment incentives will make it easier for managed care organizations to shift providers toward value-based payment models. "MIPS will reward providers who perform well on measures related to quality, resource use, clinical practice improvement, and […]
July 30, 2015 - Curant Health President and CEO, Patrick Dunham, in MedCity News - In my role as CEO of one of the nation’s largest independent 340B specialty pharmacies, I found the past six months leading up to the 340B Coalition Summer 2015 Conference were much quieter than in the past. Is the healthcare industry […]
